Reassessing Phase II Heart Failure Clinical Trials: Consensus Recommendations / Butler, Javed; Hamo, Carine E.; Udelson, James E.; O'Connor, Christopher; Sabbah, Hani N.; Metra, Marco; Shah, Sanjiv J.; Kitzman, Dalane W.; Teerlink, John R.; Bernstein, Harold S.; Brooks, Gabriel; Depre, Christophe; Desouza, Mary M.; Dinh, Wilfried; Donovan, Mark; Frische-Danielson, Regina; Frost, Robert J.; Garza, Dahlia; Gohring, Udo-Michael; Hellawell, Jennifer; Hsia, Judith; Ishihara, Shiro; Kay-Mugford, Patricia; Koglin, Joerg; Kozinn, Marc; Larson, Christopher J.; Mayo, Martha; Gan, Li-Ming; Mugnier, Pierrre; Mushonga, Sekayi; Roessig, Lothar; Russo, Cesare; Salsali, Afshin; Satler, Carol; Shi, Victor; Ticho, Barry; Van Der Laan, Michael; Yancy, Clyde; Stockbridge, Norman; Gheorghiade, Mihai. - In: CIRCULATION. HEART FAILURE. - ISSN 1941-3289. - 10:4(2017), p. e003800. [10.1161/CIRCHEARTFAILURE.116.003800]

Reassessing Phase II Heart Failure Clinical Trials: Consensus Recommendations

Metra, Marco;
2017-01-01

2017
clinical trial
heart failure
mortality
safety
United States Food and Drug Administration
Cardiovascular Agents
Clinical Trials
Phase II as Topic
Consensus
Heart Failure
Humans
Research Design
Treatment Outcome
United States
United States Food and Drug Administration
Cardiology and Cardiovascular Medicine
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/20.500.11768/193010
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 14
  • ???jsp.display-item.citation.isi??? 11
social impact